报告时间：2017年9月29日（星期五）上午8:30~12:30

地点：国际学术会议厅

 

 

报告人：

 

#1   

Le Min MD, PhD 

Assistant professor

Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA, 02115 USA 

Email:lmin@bwh.harvard.edu

 

 

Dr. Le Min is an endocrinologist at Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital and an assistant professor of Medicine at Harvard Medical School, Boston. He received his MD degree from Chongqing Medical University in Chongqing, China and a Ph.D. degree from National University of Singapore, Singapore. He had his medical residency training at Mount Sinai School of Medicine (North General) Program and a fellowship training at Brigham and Women’s Hospital, Harvard medical School. He had postdoctoral training at University of Iowa and Stony Brook University. Dr. Min is a physician scientist. He has been doing patientcare as well as translational research. His research interests focus on immune checkpoint inhibition-related endocrinopathies, metabolism and neuroendocrine regulation of reproduction. He has numerous publications in high rank peer-review journals including The Lancet Diabetes and Endocrinology,Cancer Immunology Research, Cancer Clinical Research, molecular endocrinology, and Endocrinology. He is Ad hoc Reviewer for many journals. He is awarded K08 funding from NIH. He serves as an NCI Investigational Drug Steering Committee -Immunotherapy Working Group.

#2

Yuhui Jiang

Principal Investigator

The Institute of Cell Metabolism, Shanghai Key Laboratory of Pancreatic Disease, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200080, China.

Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200080, China.

Email: yhjiang@shsmu.edu.cn

 

 

Dr. Jiang now is the principal investigator in Shanghai general hospital. He has been in the 13rd national 1000 youth talent plan (the Organization Department of the Central Committee of the CPC).  Dr. Jiang’s research focuses on the molecular mechanisms underlying tumor development and mainly applies him to the research regarding effects of altered cellular metabolism on cancer progression. In the recent 5 years, he has been investigating the exclusive functional role of metabolic enzymes: Fumarase, PKM2 in the regulation of epigenetics, cell cycle, in cancer cells and the related signaling pathways: Histone modification/assembly, ATM/DNA-PK, EGFR, mitosis checkpoint. His research work has been published in Nature cell biology, Molecular cell, Nature communications, Cancer research, Molecular and Cellular biology of which the total impact factor reaches 80.The work for the tumor metabolism has been highlighted at Nature cell biology, Cancer discovery and other authoritative journals worldwide.

 

 

#3

Jun Sun

Tenured Associate Professor

University of Illinois at Chicago, IL 60612, USA

Email: junsun7@uic.edu

 

Dr. Jun Sun is a tenured Associate Professor at the University of Illinois at Chicago. She is an elected fellow of American Gastroenterological Associate. Her key achievements include 1) characterization of vitamin D receptor regulation of microbiome in intestinal homeostasis and inflammation, 2) identification of dysbiosis and intestinal dysfunction in Amyotrophic lateral sclerosis (ALS), and 3) identification of bacteria in regulating intestinal stem cells. Dr. Sun has published over 120 scientific articles in peer-reviewed journals, including Cell Stem Cells, Nature Genetics, Gut, and JBC. She is in the editorial board of 10 scientific journals. Her research is supported by the NIH, DOD, and other awards.

 

 

 

 

#4  

Adam Marcus, PhD

Associate Professor, Emory University School of Medicine, Winship Cancer Institute

Director of the Emory Integrated Cellular Imaging Core

Director of Graduate Studies, Cancer Biology PhD program

Email: adam.marcus@emory.edu

 

Adam Marcus, PhD is an Associate Professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University. Dr. Marcus’ laboratory (marcuslab.com) studies how cancers invade and metastasize, with the goal of developing treatments that target cancer metastasis. Dr. Marcus’ research has been funded by the National Cancer Institute, American Cancer Society, the Winship Cancer Institute, private foundations, and through philanthropy. Dr. Marcus is a former Georgia Cancer Coalition Scholar, has over 75 scientific publications, and has received national and local awards for his research and teaching.  He has given numerous seminars on his research to both scientists and the general public. He was a recent TEDx speaker (https://www.youtube.com/watch?v=LgntY0dOf_c) and part of the Atlanta Innovative Index and Atlanta 40under40. Dr. Marcus serves as the Director of the Emory Integrated Cellular Imaging Core (ici.emory.edu), which provides cutting-edge imaging technologies to scientific investigators, as well as Director of Graduate Studies for the Cancer Biology PhD program.

 

Dr. Marcus also leads a science education outreach program, Citizen Science HD (citizensciencehd.com). The goals of this program are to use STEM-based initiatives in K-12 classrooms to stimulate critical thinking, diversity, and enthusiasm for the sciences. This program has visited over 35 schools, 150 classrooms, and 3000 students. In this role, he serves as the Director of the Center for Advancing Health and Diversity through Citizen Science, which is funded through the NIH. Dr. Marcus has received institutional, regional, and national awards for his teaching, outreach, and research.He also is on Twitter and can be found at @notmadscientist

 

 

#5

Guozhi Xiao

Professor and Chair 

Department of Biology and Shenzhen Key Laboratory of Cell Microenvironment, Southern University of Science and Technology, Shenzhen 518055, China

Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL 60612, United States

Email: xiaogz@sustc.edu.cn

 

Professor Guozhi Xiao is an internationally renowned bone biologist. Dr. Xiao obtained his PhD degreein biochemistry and molecular biology from Peking University in 1994, finishedhis post-doc training(1994-1998) andworked as a research track faculty(1998-2005)at the University of Michigan Ann Arbor. In 2005, he assumed an independent faculty position as a tenure-track assistant professor at the University of Pittsburgh School of Medicine andwas promoted to the level of associate professor with tenure in 2011. In 2012, he joined Rush University Medical Center in Chicago and assumed a prominent academic position as the Dr. Ralph and Marian C. Falk Endowed Chair Professor of Biochemistry and served asthe director of research of the department of biochemistry. In 2013, he joined the SUSTech as a tenured full professor and later became the chair of the biological department.Dr. Xiaohas made several contributions to our understanding the molecular control of skeletal development and homeostasis. His work is reported in more than 100 peer-reviewed publications, many in high profile journals, such as the Journal of Bone and Mineral Research (JBMR), the Journal of Biological Chemistry (JBC), the Journal of Cell Biology (JCB),Nature Communications, and the Journal of Clinical Investigation (JCI). His work has been cited more than 7000 times. He serves as a reviewer for the US National Science Foundation, the Italian Ministry of Health and the National Natural Science Foundation of China and sits on the editorial boards of the Journal of Bone and Mineral Research (JBMR) and the Journal of Biological Chemistry (JBC).Dr. Xiao’s research interests mainly focus in the following areas: (1) to determine how osteoblast, osteoclast, and chondrocyte formation is controlled during skeletal development and homeostasis under physiological and pathological conditions;(2) to define the mechanisms that modulate bone angiogenesis;(3) to study the bone-muscle interactions, and (4) to study the role of important adhesion molecule in bone and cartilage. By working on these projects, Xiao laboratory has also maintained a high focus on important medical issues involving bone – osteoporosis, osteoarthritis, metastatic osteolytic lesions, and fracture healing. Information obtained from these studies will enhance our understanding of these pathological processes.

#6

T.-C. He, MD, PhD

The University of Chicago Medical Center

Chicago, IL, USA

 

T.-C. He, MD, PhD is a well-established investigator with more than 20-year-experience in basic biomedical and translational research. His research interests include cell signaling, cancer biology, stem cell biology, gene and cell-based therapies, and regenerative medicine. He is currently a tenured faculty member and the director of Molecular Oncology Laboratory at The University of Chicago Medical Center. Dr. He completed his medical school training at Chongqing Medical University in China and received his PhD degree in molecular and cell biology from the Pennsylvania State University, followed by a postdoctoral training at Howard Hughes Medical Institute and Johns Hopkins Medical Institution. He was the principal developer of the highly-cited, widely-used AdEasy technology, which has streamlined the effective generation of recombinant adenoviruses. He has co-authored more than 190 peer-reviewed original articles, invited reviews, and book chapters, which have been cumulatively cited more than 19,900 times with a current H index of 54 according to Google Scholar. In addition to his research activities, Dr. He has actively participated in the peer reviewing process for more than 30 journals, including many top tier journals. He is currently serving on the editorial boards for over 10 journals, including Journal of Biological Chemistry, Current Cancer Drug Targets, Laboratory Investigation, and American Journal of Stem Cells.

#7

Fei Li, MD, PhD

University of Illinois at Chicago

Chicago, IL, USA

 

Following undergraduate and graduate studies in West China University of Medical Sciences and Chongqing Medical University, Fei Li received his PhD in Pharmacology and Toxicology in 1992 from Medical College of Virginia, Virginia Commonwealth University for his study on protein kinase C and bone marrow stem cell differentiation. He completed his postdoctoral training in bone marrow stem cell gene transfer at the National Institutes of Health in 1997. From 1997 to present he has been appointed as research faculty at University of Illinois at Chicago. His current research area includes phenotypical and functional analysis of endothelial differentiation from human and mouse embryonic stem cells and induced pluripotent stem cells.